Breaking news on liver disease, hepatitis
Successful Completion Of First Clinical Trials On Potent New Hepatitis C Drug published
Mon, 06 Sep 2010 01:00:00 PDT
The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed...
NIH Awards $1.2 Million To Study Protein Misfolding Diseases published
Fri, 03 Sep 2010 04:00:00 PDT
Three University of Massachusetts Amherst scientists have received a four-year, $1.2 million EUREKA grant from the U.S. National Institutes of Health (NIH) to study folding and misfolding of secretory proteins in the cell's protein factory, the endoplasmic reticulum, where misfolding can lead to diseases such as cystic fibrosis and liver cirrhosis...
New Partnership Forms To Address The Hepatitis B And C Epidemic In Europe published
Fri, 03 Sep 2010 03:00:00 PDT
At least 23 million European Union (EU) citizens are currently living with hepatitis B or hepatitis C,[i] both cancer-causing viruses...
Inhibitex Successfully Completes Phase 1a Trial Of INX-189 published
Fri, 03 Sep 2010 02:00:00 PDT
Inhibitex, Inc. (Nasdaq: INHX), announced that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo...
Macmillan's Response To NICE Decision On Liver Cancer Drug published
Fri, 03 Sep 2010 01:00:00 PDT
Responding to the decision by the National Institute for Health and Clinical Excellence (NICE) not to recommend sorafenib (Nexavar®) as a treatment for advanced liver cancer, Mike Hobday, Head of Campaigns at Macmillan Cancer Support, said: 'We are extremely disappointed that NICE has decided not to recommend sorafenib as a treatment for people with advanced liver cancer...
Abbott Receives FDA Approval For First Automated Molecular Test For Assessing Hepatitis B Treatment published
Thu, 02 Sep 2010 02:00:00 PDT
Abbott (NYSE: ABT) announced it has received approval from the U.S. Food and Drug Administration (FDA) to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus (HBV) in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results...
Beaumont Hospitals Launches New Liver Transplant Program published
Thu, 02 Sep 2010 02:00:00 PDT
Beaumont Hospital, Royal Oak became Michigan's third liver transplant center on Aug. 31. A 59-year-old man from Royal Oak was the first patient to receive a liver transplant through Beaumont's new multi-organ transplant program. Under the leadership of Alan J. Koffron, M.D...
Innovative Low Cost, High-Speed Filter Uses Electrified Nanostructures To Purify Water published
Wed, 01 Sep 2010 03:00:00 PDT
By dipping plain cotton cloth in a high-tech broth full of silver nanowires and carbon nanotubes, Stanford researchers have developed a new high-speed, low-cost filter that could easily be implemented to purify water in the developing world. Instead of physically trapping bacteria as most existing filters do, the new filter lets them flow on through with the water...
Liver Expert Robert Gish, MD, Joins UC San Diego published
Tue, 31 Aug 2010 05:00:00 PDT
Robert G...
Bleeding In Cirrhosis Patients May Be Reduced By Adherence To Practice Guidelines published
Mon, 30 Aug 2010 01:00:00 PDT
Compliance with practice guideline-recommended treatment for cirrhosis is associated with a reduction in first esophageal variceal hemorrhage (EVH; bleeding), according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. Cirrhosis is a condition in which the liver is permanently scarred or injured...
Liver Cells Created From Patients' Skin Cells published
Sun, 29 Aug 2010 00:00:00 PDT
By creating diseased liver cells from a small sample of human skin, scientists have for the first time shown that stem cells can be used to model a diverse range of inherited disorders. The University of Cambridge researchers' findings, which will hopefully lead to new treatments for those suffering from liver diseases, were published in The Journal of Clinical Investigation...
Aethlon Medical Announces Approval Of Hepatitis C Virus (HCV) Treatment Program published
Fri, 27 Aug 2010 03:00:00 PDT
Aethlon Medical, Inc...
China PharmaHub Corp. Introduces A 'Magic Bullet' Liver Cancer Therapy To China, Hong Kong, Taiwan, Macau, Singapore, Malaysia, And Bangladesh published
Fri, 27 Aug 2010 02:00:00 PDT
China PharmaHub Corp...
ZymoGenetics Announces Completion Of Enrollment In Phase 2b Clinical Trial With PEG-Interferon Lambda In Hepatitis C published
Fri, 27 Aug 2010 01:00:00 PDT
ZymoGenetics, Inc. (NASDAQ:ZGEN) announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection. ZymoGenetics is investigating PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company (NYSE:BMY) for the treatment of HCV infection...
Stem Cell Technology Applied To Liver Diseases published
Thu, 26 Aug 2010 03:00:00 PDT
Great excitement greeted the discovery a few years ago that certain cells from mice and humans could be reprogrammed to become inducible pluripotent stem cells (iPS cells), as they hold promise for cell replacement therapy and modeling human disease...
Alcoholic Liver Disease Is More Aggressive Than Other Chronic Liver Diseases published
Thu, 26 Aug 2010 00:00:00 PDT
Many diagnostic and treatment options have been developed for chronic liver disease during the last 40 years, yet their influence on survival remain unclear...
Skin Converted Into Liver Cells - Potential Cell-based Therapy For Patients With Liver And Other Diseases published
Wed, 25 Aug 2010 14:00:00 PDT
Researchers have managed to convert skin from individuals with metabolic diseases into liver cells using stem cell technology, according to an article published in the Journal of Clinical Investigation. This research will allow scientists to determine precisely what is happening in a diseased liver cell, then try out potential treatments...
Celsion Receives Fast Track Designation For ThermoDox® Development Program To Treat Primary Liver Cancer published
Wed, 25 Aug 2010 02:00:00 PDT
Celsion Corporation (Nasdaq: CLSN), a leading oncology drug development company, announced that the U.S. Food and Drug Administration (FDA) has designated the HEAT Study of its investigational drug, ThermoDox®, in combination with radiofrequency ablation (RFA), as a Fast Track Development Program...
Pharmasset Initiates Phase 2b Clinical Trial Of PSI-7977 For Chronic Hepatitis C Genotypes 1, 2, And 3 published
Wed, 25 Aug 2010 02:00:00 PDT
Pharmasset, Inc. (Nasdaq: VRUS) announced that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV)...
Cumberland Pharmaceuticals Announces Extension Of FDA Review Of Acetadote® Supplemental New Drug Application published
Tue, 24 Aug 2010 01:00:00 PDT
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced the U.S. Food and Drug Administration (FDA) has extended its review of the supplemental new drug application (sNDA) for the use of Acetadote® (acetylcysteine) Injection in patients with non-acetaminophen acute liver failure...
Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within A Response-Guided Regimen For People With Hepatitis C published
Sat, 21 Aug 2010 02:00:00 PDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR)...
Hispanics And Asians Less Likely To Receive Liver Transplants published
Fri, 20 Aug 2010 03:00:00 PDT
Researchers at the University of Michigan and Arbor Research Collaborative for Health, both in Ann Arbor, have identified geographic variation as a key factor accounting for disparities in access to liver transplantation among racial and ethnic groups...
Hepatitis C And B Undetected In Over Half A Million People In UK published
Fri, 20 Aug 2010 02:00:00 PDT
Have you ever felt under the weather but the doctor has been unable to diagnose what is wrong with you? Have you ever shared your partner's toothbrush or borrowed your friend's razor? It is possible that you could be suffering from a disease which often goes untested. It is estimated that over half a million people in the UK are living with hepatitis B or C without knowing it...
Multi-centre Phase II Trial Reports Safety And Clinical Benefits Of Radioactive Microspheres In Patients With Colorectal Cancer Liver Metastases published
Fri, 20 Aug 2010 02:00:00 PDT
Radioactive yttrium-90 labelled resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to be a safe and effective treatment for patients with colorectal cancer liver metastases who have failed available chemotherapy options, according to the final results of a prospective clinical multi-centre phase II trial conducted by the Italian Society of Locoregional T...
Identifying Factors Which Predict Alcohol Use After Liver Transplantation published
Fri, 20 Aug 2010 00:00:00 PDT
Patients who receive a liver transplant due to alcoholic liver disease need to demonstrate periods of abstinence and often attend addiction treatment before transplantation. However, alcohol use disorders can recur, as can other diseases requiring transplantation, and thus alcohol use after liver transplantation is not uncommon...
)
|
|
